India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#336- Valuation
- ₹16,860 Cr
2022 #341 2021 #394
Please enter your name.
Please enter a valid email address.
Please select an issue type.
Please add a few details about the issue.
About Biological E
Biological E is a publicly listed company based in Hyderabad (India) founded in 1953 by Datla Venkata Krishnam Raju. Vaccines and therapeutics for multiple diseases are developed and marketed. The company has 6,099 employees. Biological E has completed 2 acquisitions, including Akorn and Akorn India. Its chief executive, as recorded, is Mahima Datla. Its website biologicale.com draws about 25 thousand monthly visits. Its Indian entity Biological E. Limited reported revenue of ₹5,053 Cr. Biological E offers products and services including CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic.
Company details
Biological E was founded in 1953 in Hyderabad, India, as a biopharmaceutical company. Innovative vaccines, branded generics, and novel therapeutics are developed, manufactured, and marketed globally. The product pipeline encompasses pneumococcal conjugate vaccine, Hib vaccine, poliomyelitis vaccine, COVID-19 vaccine, hepatitis A vaccine, and measles vaccine. Operations are centered on addressing various infectious diseases through research and production.
Recognitions & Rankings of Biological E
- Headquarters Hyderabad, India
- Employees 6,099
- Founders Datla Venkata Krishnam Raju
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website biologicale.com
- Social LinkedIn X Facebook
- Legal Name Biological E. Limited
- Date of Incorporation 10 Dec, 1953
- Jurisdiction Telangana, India
Operational Areas
Key Metrics
- Annual Revenue₹5,053 Cr
FY 2025 · +87% YoY
- Net Profit₹756 Cr
FY 2025 · 15% margin
- EBITDA₹1,354 Cr
FY 2025 · 28% margin
- Latest Funding Round$50M (USD), Debt – Conventional
Oct 2021
- InvestorsInternational Finance Corporation
& 1 more
- Employee Count6,099
- Investments & AcquisitionsAkorn
& 1 more
Associated legal entities of Biological E
Biological E operates through Biological E. Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Biological E. Limited CIN U01120TG1953PLC001095 | Active | 10 Dec 1953 | Hyderabad, Telangana | ₹5,053 Cr | 6,577 | 10 | View details |
Products & Services of Biological E
Biological E offers a comprehensive portfolio of products and services, including CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine.
CORBEVAX
Vaccine
Vaccine for preventing SARS-CoV2 infections.
Hepatitis B Vaccine
Vaccine
Vaccine to prevent Hepatitis B disease.
Pentavalent Vaccine
Vaccine
Combined vaccine for diphtheria, tetanus, pertussis, hepatitis B, and Hib.
Typhoid Conjugate Vaccine
Vaccine
Vaccine against typhoid fever in children and adults.
Funding Insights of Biological E
- Total Rounds 4
- Last Round Debt – Conventional — $50M
- First Round $60M
(May 2017)
- Investors Count 2
All 4 funding rounds of Biological E with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
Valuation history
2 investors in total: 2 institutional.
Investors in Biological E
Biological E has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include International Finance Corporation and DFC.
All
Venture Fund
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency supporting the development of SMEs | 2019 | dfc.gov | ||
IFC is focused on private sector development in emerging markets. | 1956 | ifc.org |
Premium access
Investor details for Biological E
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Biological E. Limited (Biological E)
Biological E. Limited is the primary company behind Biological E. The board of Biological E. Limited currently have 9 directors; the longest-serving is Mahima Datla, appointed in 2013. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mahima Datla DIN 00965039 | Managing Director | 10 Apr 2013 | 13 yrs 7 mo | Biological E. Limited |
| Ippagunta Yasodhara Rama Krishna Rao DIN 00481367 | Director | 23 May 2017 | 9 yrs 5 mo | Biological E. Limited |
| Rudaraju Anand Kumar DIN 07964480 | Whole-time director | 16 Oct 2017 | 9 yrs | Biological E. Limited |
| Indira Smriti Rajupusapati DIN 00482381 | Whole-time director | 20 Dec 2023 | 2 yrs 10 mo | Biological E. Limited |
| Mantena Purnima DIN 00965007 | Whole-time director | 20 Dec 2023 | 2 yrs 10 mo | Biological E. Limited |
| Narsing Rao Singayapally DIN 00800362 | Additional Director | 07 Oct 2024 | 2 yrs 1 mo | Biological E. Limited |
| Narender Dev Mantena DIN 01000558 | Whole-time director | 07 Oct 2024 | 2 yrs 1 mo | Biological E. Limited |
| Venkata Subbaraju Penmetsa DIN 00028230 | Additional Director | 07 Oct 2024 | 2 yrs 1 mo | Biological E. Limited |
| Peter Baron Piot DIN 09015343 | Additional Director | 27 Nov 2024 | 1 yr 11 mo | Biological E. Limited |
People of Biological E
109 people are tracked at Biological E (39 in leadership, 70 in team); the tracked headcount is 6,099.
| Name | Role | Group |
|---|---|---|
Datla Venkata Krishnam Raju | Founder | Leadership |
| CEO & Managing Director | Leadership | |
Ganesh Prasad Mishra | General Manager Business Development | Leadership |
Aln Reddy | Sr Vice President | Leadership |
Mahesh Kyasani | General Manager | Leadership |
Prashant Chawla | Sr. General Manager | Leadership |
Vijay Kumar Sarakamu | Head - International Sales And Marketing (vaccines Bu) | Leadership |
Vishvesh Kumar Bhupathiraju | COO, Pharma Specialty Generic Injectables | Leadership |
Lakshminarayana Neti | Chief Operating Officer | Leadership |
Ganapathi Raju | Associate Vice President | Leadership |
Dr. Satya Babu | Sr. VP And Head - Quality, Regulatory And Scientific Affairs, Head - Operations Paonta Unit | Leadership |
Venkatesh R | Chief Financial Officer | Leadership |
Subbarao Pandit Vallarapu | General Manager IT | Leadership |
Vijay Amruth Raj | General Manager, Corporate Communications | Leadership |
Anandaraman Santhanam | HEAD Project & Engineering IN THE Capacity OF GM | Leadership |
Shanmukh Rao Kota | Asst General Manager - Business Development & Global Portfolio | Leadership |
Mitali Chakraborty | Head Of Marketing | Leadership |
Vikram Paradkar | Executive Vice President | Leadership |
Ramesh Gunda | Vp- Accounts And Finance | Leadership |
Ramakrishna Chigurambotla | General Manager | Leadership |
89 more people are available in the full profile.
Premium access
Complete people profiles for Biological E
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Biological E
Figures of Biological E. Limited, the primary company behind Biological E, for FY 2025. Revenue was ₹5,053 Cr (+87% year on year). Net profit was ₹756 Cr (15% margin). EBITDA was ₹1,354 Cr (28% margin). Revenue has grown at a compounded annual rate of +24% over three years and +1252% over five years.
- ₹5,053 CrRevenue · FY 2025 · +87% YoY
- ₹756 CrNet profit · 15% margin
- ₹1,354 CrEBITDA · 28% margin
- ₹4.95 CrPaid-up capital
- 6,577Employees (provident fund records)
- +24%Revenue CAGR, 3 years
- +1252%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Biological E. Limited are on its company page.
Premium access
Detailed financial statements for Biological E
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biological E
Biological E has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Akorn and Akorn India.
Acquisitions
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Sterile pharmaceuticals are developed, manufactured, and marketed by Akorn India. | akornindia.com | Gurugram, India | 2011 | Aug 2020 | $10M | |
Injectable and ophthalmic pharmaceutical products were manufactured across therapeutic areas. | akorn.com | Lake, United States | 1948 | Aug 2020 | •••• |
Premium access
Complete acquisition details for Biological E
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biological E
6 dated milestones of Biological E across 69 years, from founding to its latest funding, stage changes and deals.
- Founded Biological E is founded.
- Funding First funding round of $60.0M.
- Acquisition Acquires Akorn.
- Acquisition Acquires Akorn India.
- Funding Latest funding round, Debt – Conventional, of $50.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Biological E
The website of Biological E (biologicale.com) receives about 24.8K visits a month.
- Monthly visits24.8K
▲ 199.2% vs previous month
Similar websites
Websites whose visitors overlap most with Biological E. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| qualitybiological.com | 78% | 5.9K | #3,332,912 | View details |
Upgrade to premium
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biological E
Premium access
Complete news archive for Biological E
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biological E
Biological E was founded in 1953 and raised its 1st funding round 64 years after it was founded.
Biological E is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Mahima Datla is the CEO of Biological E, as recorded in our data.
Biological E has 6,099 employees.
The primary company behind Biological E, Biological E. Limited, reported revenue of ₹5,053 Cr for FY 2025, up 87% year on year.
Biological E was founded in 1953 in Hyderabad, India, as a biopharmaceutical company. Innovative vaccines, branded generics, and novel therapeutics are developed, manufactured, and marketed globally. The product pipeline encompasses pneumococcal conjugate vaccine, Hib vaccine, poliomyelitis vaccine, COVID-19 vaccine, hepatitis A vaccine, and measles vaccine. Operations are centered on addressing various infectious diseases through research and production.
Biological E offers CORBEVAX, Hepatitis B Vaccine, Pentavalent Vaccine, and Typhoid Conjugate Vaccine.
Biological E has made 2 acquisitions, including Akorn, and Akorn India.
Biological E has 2 investors. Key investors include International Finance Corporation, and DFC.
Biological E operates through Biological E. Limited.
The legal entities of Biological E currently have 10 directors, including Narsing Rao Singayapally, Peter Baron Piot, Rudaraju Anand Kumar and others.